• Plus Therapeutics unit CNSide Diagnostics won Medicare enrollment, securing CMS Provider Transaction Access Number for its CNSide cerebrospinal fluid assay platform.
• Status allows CNSide to submit Traditional Medicare claims for its tumor cell enumeration test, subject to local Medicare Administrative Contractor coverage decisions.
• Enrollment sets up pursuit of Medicare Advantage coverage, expanding addressable patients beyond Traditional Medicare toward roughly 35 million Medicare Advantage beneficiaries.
• CNSide plans to seek Medicare coverage determinations, with CMS pricing for CPT code 0640U slated to take effect for billing July 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.